Browsing Tag
neurology
9 posts
Can UPLIZNA transform gMG treatment? Amgen’s FDA win sets new benchmark for antibody-positive patients
Discover how Amgen’s UPLIZNA is redefining generalized myasthenia gravis treatment after FDA approval. Find out what this means for patients and investors.
Can zilganersen become the first disease-modifying therapy for Alexander disease?
Ionis wins FDA breakthrough therapy status for zilganersen in Alexander disease. Find out what this means for rare neurology drug development.
Is Aptamer Group (LON: APTA) finally seeing sustained pharma traction with its Optimer platform?
Aptamer Group grows FY26 contracts to £1.95M with pharma repeat wins. Find out how its IP-heavy Optimer platform is gaining commercial traction.
Skyhawk Therapeutics and Merck sign $2bn RNA drug discovery pact targeting neurological disorders
Skyhawk Therapeutics inks $2B Merck deal to develop RNA-targeted neurology drugs, highlighting splicing modulation as a new frontier.
Inside the $6bn bet: How XtalPi and DoveTree plan to reshape drug discovery with AI and robotics
XtalPi and DoveTree strike a US$6 billion AI drug discovery deal blending quantum simulation, robotics, and biology to target complex diseases.
Takeda’s oveporexton Phase 3 trials show broad success in narcolepsy type 1, paving way for 2025 FDA submission
Takeda announces pivotal Phase 3 trial results for oveporexton (TAK-861), showing statistically significant improvements in narcolepsy type 1 symptoms. Regulatory filings planned.
Vyepti by H. Lundbeck A/S shows robust Phase IV efficacy in chronic migraine with medication-overuse headache patients
H. Lundbeck A/S reports rapid and significant migraine prevention benefits for Vyepti® (eptinezumab) in Phase IV RESOLUTION trial, targeting MOH patients.
ENCell announces promising results from Phase 1 CMT1A trial of EN001
ENCell Co., Ltd., a South Korean biotech leader specializing in Cell and Gene Therapy (CGT), has unveiled promising…
FDA approves Genentech’s Ocrevus for multiple sclerosis treatment
In a landmark decision, the US Food and Drug Administration (FDA) has granted approval to Genentech, a subsidiary…